Additional file 1: Figure S1. of FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine

Abstract

PAK1 Knock-down (KD) effects on survival and ERK expression. PAK1 KD cells were measured in the presence (darker bars) and absence (lighter bars) of FBS to measure survival, using thymidine-withdrawal. Survival in PANC-1 PAK1 KD clones (A) was significantly lower but no difference was observed in MiaPaCa-2 PAK1 KD clones (B). No reduction in the expression of either phospho-ERK (pERK1/2) or total ERK (ERK1/2) was detected in either PANC-1 (C) or MiaPaCa-2 (D) PAK1 KD cells, as assessed by western blot. The data represent mean ± SEM, summarised from three independent experiments. *** p < 0.001, compared to the corresponding clone with FBS. (PPTX 433 kb

    Similar works

    Full text

    thumbnail-image

    Available Versions